Paper Details

  1. Home
  2. Paper Details

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.

Author: CatesChristopher J, DucharmeFrancine M, LassersonToby J

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

In adults with asthma inadequately controlled on inhaled steroids and showing reversibility with beta(2)-agonists, LABA is superior to LTRA in reducing oral steroid treated exacerbations. There is some evidence of increased risk of SAEs with LABA.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta(2)-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered as add-on therapy to ICS. OBJEC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD003137.pub4

データ提供：米国国立医学図書館（NLM）

Asthma Management: Finding the Right Path

Asthma, a chronic respiratory condition, affects millions of people worldwide. This study investigates the effectiveness of two different add-on therapies for asthma patients who continue to experience symptoms despite regular inhaled corticosteroids (ICS): long-acting beta(2)-agonists (LABA) and anti-leukotrienes (LTRA). The researchers compared the efficacy and safety of these treatments in adults and children with asthma, analyzing data from multiple clinical trials. Their findings suggest that LABA may be a superior option for adults with asthma compared to LTRA in reducing the risk of exacerbations.

LABA: A Potential Advantage for Asthma Management

This research provides valuable insights into the management of asthma. The analysis of 17 clinical trials, including both adults and children, suggests that LABA, when added to ICS, may be more effective in reducing the risk of asthma exacerbations compared to LTRA. The study also found that LABA resulted in greater improvements in lung function, functional status, and quality of life, suggesting its potential for enhancing overall asthma control.

Managing Asthma: A Collaborative Effort

Asthma is a complex condition, and managing it effectively requires a collaborative effort between patients and their healthcare providers. This research highlights the potential benefits of LABA as an add-on therapy for adults with asthma. It's a reminder that understanding the various treatment options available and working closely with your healthcare provider is key to managing asthma effectively and living a fulfilling life.

Dr.Camel's Conclusion

Asthma can feel like a relentless desert wind, making it difficult to breathe. This study offers a beacon of hope, highlighting the potential of LABA as an effective add-on therapy for asthma management. It's a reminder that even in the vast desert of respiratory challenges, there are oases of innovation and treatment breakthroughs waiting to be discovered.

Date :
  1. Date Completed 2011-06-23
  2. Date Revised 2020-05-11
Further Info :

Pubmed ID

21563136

DOI: Digital Object Identifier

10.1002/14651858.CD003137.pub4

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.